According to the annual report of the home ministry for 2021-22, during the second wave of coronavirus in the country, it had coordinated with the states and Union territories and various stakeholders concerned for ensuring the supply of medical oxygen for treatment of moderate to severe COVID-19 patients.
An international team led by researchers from the University of Kent in the UK and the Goethe-University in Germany tested the sensitivity of different SARS-CoV-2 Omicron and Delta viruses to combinations of the four currently approved antiviral drugs with betaferon.
The patients were being administered paracetamol, and not Remdesivir drug, which was used for patients in the first and second COVID-19 waves, they said.
Until now, the Government of India used to allow restricted export of injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) – a drug that is used in COVID-19 treatment.
The research, published recently in the journal Nature, suggests that these drugs are more potent when used in combination than individually.
The prices of drugs and medical devices in India have long been under the scanner for unaffordability to a large chunk of the population but the government now claims that it is trying to fix a trade margin ceiling for many drugs, including the ones used in COVID treatment, to make them easily accessible to people.
According to the clinical guidance issued by the Union health ministry for management of the infection in adult patients, Remdesivir has been asked to be used in patients with moderate to severe COVID-19 and those with no renal or hepatic dysfunction within 10 days of onset of any symptom.
The 50 lakh vials of Remdesivir have been kept as a reserve for immediate release to states if the need emerges.
Drug makers had ramped up their capacity to make Remdesivir amid acute scarcity during the second wave of the coronavirus pandemic, but demand has crashed in step with the steep fall in the number of new cases.
A bench headed by Justice D Y Chandrachud had slammed the Centre's Covid vaccination policy, describing as "prima facie arbitrary and irrational" allowing states and private hospitals to charge those in the 18-44 age group while the jabs were offered free for groups in the first two phases, and ordered its review.
The export of Remdesivir injections and APIs against the Advance Authorization shall no longer require a separate export authorisation or permission as, under the revised policy, the drug has been moved from 'prohibited' to 'restricted' category.
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well
The Ministry of Chemicals and Fertilizers said that the production of remdesivir had been ramped up ten times from 33,000 vials/day on April 11, 2021, to 3,50,000 vials/day on May 29.
The Uttar Pradesh government will contain the second wave of COVID-19 by the end of May, Chief Minister Yogi Adityanath said.
Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic
Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold
In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets
The Hyderabad-based company has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and marketing of the drug in India.
The Karnataka government has said that the Centre had directed Jubilant Ltd to supply 32,000 Remdesevir vials to the state by May 9. However, Karnataka has only received 17,601 vials from the company as of May 8.
"The companies have been instructed to ensure timely supplies to all states/ UTs strictly as per the supply plan," the Ministry of Chemicals and Fertilizers said in a statement.
They are also working with regulatory authorities and the government of India to donate Lilly’s COVID-19 treatments, including Baricitinib, if authorities deem it appropriate to potentially provide relief
Prior to this, a flight carrying 1,000 oxygen cylinders, regulators pulse oxymeters and N95 masks landed in India on May 1, while another flight with 1.25 lakh vials of Remdesivir landed on May 2.
While drugs like Remdesivir, Tocilizumab, Favipiravir and others are exempt from customs duties as well as IGST, there is still no clarity on the GST they would attract when manufactured in India.
The apex court suggested that India could obtain a licence from Bangladesh to produce a generic version of the drug locally.
Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs